STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT01702636

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01702636
Other papers using this trial's data
  • Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial The Lancet. Neurology, 2020-12 DOI, PubMed 33128912

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, Finland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01702636. Randomized; quadruple masking; primary purpose treatment. Start 2012-12 (actual); primary completion 2019-08-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial
Acronym
STOP-AUST
Condition
Intracerebral Haemorrhage
Condition
Stroke
Intervention (Drug)
Tranexamic Acid
Intervention (Drug)
Placebo
Lead sponsor
Neuroscience Trials Australia (class: other)

Record details

Record id
cardio:ct-nct01702636
Content hash
8c5e63dc38df0fbeb3e5abeb452281c0f7cbb8b01ec1c1d72882dbdf3aff8b0d